ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
32 announcements
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure has filed its Notice of the 31st Annual General Meeting and the Annual Report for the financial year ended March 31, 2026.
Poly Medicure has announced a record date of August 29, 2026, for a final dividend of ₹3.50 per equity share for FY 2025-26.
Poly Medicure Limited has scheduled its 31st Annual General Meeting for September 05, 2026, to transact ordinary and special businesses, including dividend declaration.
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
Poly Medicure Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's paid-up share capital.
Poly Medicure Limited has re-appointed M/s. Jai Prakash & Company as Cost Auditors for the company.
Poly Medicure Limited announced the resignation of Mr. Ravi Prakash from his position as Deputy Company Secretary, effective August 10, 2026.
Poly Medicure reported strong Q1 FY27 consolidated revenue growth of 30.3% YoY, driven by acquisitions (Citieffe, PendraCare) and domestic expansion. Strategy shifts towards high-complexity medical devices like Cardiology and Orthopaedics.
Poly Medicure Ltd reported revenue from operations of ₹525.4 Cr (+30.3% YoY) and net profit of ₹85.3 Cr (-8.4% YoY) for Q1 FY27.
Poly Medicure Limited has scheduled a Board Meeting on August 7, 2026, to consider and approve the unaudited financial results for the quarter ending June 30, 2026.
Poly Medicure Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended June 30, 2026. This is a routine periodic regulatory disclosure.
Poly Medicure disclosed that the Delhi High Court stayed the stamp duty order dated 15 June 2026. The case is ongoing and the company will update investors.
CRISIL reaffirmed Poly Medicure's Short Term Rating at A1+ and revised Long Term Rating outlook to 'Positive'. Total rated facilities amount to ₹500 Crore.
Poly Medicure received a ₹2.50 Crore demand including penalty for alleged stamp duty deficits on share allotments. The company intends to legally challenge the order.
Poly Medicure received a stamp duty demand of Rs.2.50 Crore including penalty. The company is challenging the order legally and expects no material financial impact.
Poly Medicure appointed Mr. Indranil Mukherjee as CEO for Asia Pacific and India Business. This strategic leadership addition aims to drive regional market expansion and operational growth.
Poly Medicure reported FY26 consolidated revenue of ₹1,875cr (up 12.3%) and standalone EBITDA of ₹446cr (26.8% margin). The company is transitioning from product-focused to therapy-focused segments like Cardiology and Renal.
Poly Medicure Ltd cancelled its physical one-on-one meeting with Trust AMC scheduled for May 27, 2026. Investors should note the withdrawal of this scheduled interaction.
Poly Medicure reported audited FY26 results and recommended a ₹3.50 per share dividend. The Board also re-appointed PwC and Oswal Sunil & Co as internal auditors.
Poly Medicure reported FY2025-26 audited results and recommended a final dividend of Rs 3.50 per share. Net profit for the year reached ₹335.82 Crore.
Poly Medicure reported zero deviation in utilizing ₹1000.0 Crore raised through a QIP. The Audit Committee reviewed the deployment of proceeds during the March 2026 quarter.
Poly Medicure delivered solid revenue growth despite geopolitical and raw material headwinds, successfully pivoting towards high-margin oncology, renal, and cardiology segments while integrating key acquisitions.
Poly Medicure (Polymed) reported FY26 consolidated revenue growth of 12.3% YoY. The company is transitioning towards high-end technology segments like Cardiology and Orthopaedics through strategic European acquisitions (Citieffe, PendraCare).
Poly Medicure reported Q4 FY26 consolidated revenue growth of 21.3% YoY. The company is scaling via acquisitions like Citieffe and PendraCare while maintaining strong standalone ROIC above 20%.
Poly Medicure delivered strong FY26 performance with 12.3% consolidated revenue growth and significant gross margin expansion. Strategy focuses on high-end tech segments through Citieffe and PendraCare acquisitions.
Poly Medicure Ltd reported revenue from operations of ₹534.5 Cr (+21.3% YoY) and net profit of ₹65 Cr (-29.2% YoY) for Q4 FY26.
Poly Medicure Limited reported audited financial results for FY2025-26 and recommended a Rs 3.5 dividend per share. The board also re-appointed internal auditors for the next year.
Poly Medicure granted 17,500 stock options at ₹100 per share under its 2020 ESOP scheme. The options vest over four years, aligning employee and shareholder interests.
Poly Medicure scheduled a board meeting on May 25, 2026. The board will consider audited financial results and a potential final dividend recommendation.